CClinicalTrials.gg
CompletedNCT05754229Updated Aug 27, 2026

Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

An interventional study of AI-assisted colonoscopy in Colorectal Cancer, Colorectal Adenoma and Colorectal Neoplasms, sponsored by Ismail Gögenur. Completed at 4 sites in Denmark. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Ismail Gögenur · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Oct 2022, registered Feb 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
395
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are:

  • How high is the specificity of the AI system when characterizing colorectal polyps

Participants will receive a standard colonoscopy, assisted by the artificial intelligence (AI) assisted system GI Genius.

Researchers will compare the AI system´s characterization with the histopathology to see how accurate the system is.

Read the detailed description

Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.

Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.

Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Studies have shown that AI contributes to a significantly higher adenoma detection rate (ADR), compared colonoscopies without assistance of an AI system.There have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI-system, since the increased detection of small polyps may lead to unnecessary polypectomy.

With the development of computer-aided polyp characterization (CADx) systems, it is possible to use AI for decision support and not only for detection. There is no evidence yet that the CADx system increases the sensitivity for small neoplastic polyps when used by non-expert endoscopists (accredited for standard colonoscopy), but it may improve the clinicians confidence, and increase the specificity for optical diagnosis (Barua et al).

Diminutive polyps (1-5 mm) in the rectosigmoid colon can be left in situ when diagnosed with high confidence with a sensitivity of at least 90% and a specificity of at least 80%. To implement the resect-and-discard strategy, a sensitivity of at least 80% is acceptable. This is recommended by the European Society of Gastrointestinal Endoscopy (ESGE) as a strategy to decrease the unnecessary removal of small polyps with a negligible risk of harbouring cancer. Although the resect-and-discard strategy is assessed to be a safe and cost-effective method, it is important to be cautious with lesions in the right colon due to their malignant potential.

Reliable CADx systems could enable a more targeted removal of neoplastic polyps, while diminutive non-neoplastic polyps could be left behind. The potential excessive workload due to the CADe system could therefore theoretically be avoided by adding the CADx system.

The results so far are promising, suggesting that AI-assisted colonoscopy is superior to conventional colonoscopy when it comes to polyp and adenoma detection. Continued improvement of CADx systems in differentiating the pathology of colorectal lesions is needed, as well as additional clinical studies to assess the potential value of the CADx system.

The overall aim of this research is to investigate the quality, and the possible benefits of AI-assistance in colonoscopy. Hopefully this can contribute to a more accurate, safe, and targeted diagnosis and treatment of patients in the future.

The investigators have designed a quality assurance study to investigate the effect of real time AI-assisted colonoscopy with the CADx system (GI Genius, Medtronic). This study "REG-093-2022" is a substudy to the RCT "REG-092-2022". The investigators wish to evaluate the diagnostic accuracy of the CADx system.

02

Conditions studied

  • Colorectal Cancer
  • Colorectal Adenoma
  • Colorectal Neoplasms

Keywords

  • Artificial intelligence-assisted colonoscopy
  • Computer-aided polyp characterization
  • Colorectal adenoma
03

In context

Colorectal Neoplasms

5,599 studies on the registry are indexed under Colorectal Neoplasms; 1,458 are open to participants now.

This study's enrollment of 395 is above the median of 77 across 4,122 interventional studies indexed under Colorectal Neoplasms.

Browse Colorectal Neoplasms studies →

Lead sponsor

Ismail Gögenur is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
  • Diagnostic colonoscopy due to symptoms/signs or
  • Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)

Exclusion criteria

Exclusion Criteria:

  • Referral for removal of previous detected polyps
  • Emergency colonoscopy
  • Control colonoscopy due to inflammatory bowel disease (IBD)
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
395 participants (actual)

Study arms

  • Other
    AI-assisted colonoscopy

    The patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).

    Device: AI-assisted colonoscopy

Interventions

  • DeviceAI-assisted colonoscopy

    The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).

06

What researchers measure

Primary outcomes

  1. True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Time frame: 5 Months

  2. True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Time frame: 5 Months

  3. False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Time frame: 5 Months

  4. False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Time frame: 5 Months

07

Study locations

4 sites
  • Holbæk Hospital
    Holbæk, 4300, Denmark
  • Zealand University Hospital
    Køge, 4600, Denmark
  • Nykøbing Falster County Hospital
    Nykøbing Falster, 4800, Denmark
  • Næstved Hospital
    Næstved, 4700, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05754229
Lead sponsor
Ismail Gögenur
Collaborators
Nykøbing Falster County Hospital, Naestved Hospital, Holbaek Sygehus, Slagelse Hospital
Responsible party
Ismail Gögenur (Professor, DMSc, Zealand University Hospital) — Sponsor-investigator
First posted
Mar 3, 2023
Start date
Oct 1, 2022
Primary completion
Mar 3, 2023
Completion
Apr 21, 2026
Last update
Aug 27, 2026

Study contacts

Ronja Lagström, MD
principal investigator · Zealand University Hospital, Køge

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion